Featured Lymphoma Content
Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the clinical treatment options for patients with relapsed Hodgkin lymphoma and anaplastic large cell lymphoma.
Lymphoma News and Features
Lenalidomide is an effective treatment option with limited and reversible toxicities for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), a 'real-world' study has shown.
Recent results from a multicenter, phase 2 trial suggest that patients with HIV and aggressive lymphoma should receive autologous stem cell transplant as standard of care. Risk of serious complications after transplant in these patients is equal to that of patients without HIV.
Patients living with HIV are at high risk for lymphoma,according to recent study data, and recent autologous hematopoietic stem-cell transplantation may be preferable for these patients.
Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma.
Patients with classical Hodgkin lymphoma who are resistant to the CD30-directed antibody-drug conjugate brentuximab vedotin have poor outcomes.
A weekly dose of temsirolimus 75 mg was found to be active in patients with relapsed/refractory primary CNS lymphoma (PCNSL); however, only some patients achieved long-term control.
A new approach in T cell immunotherapy uses a small protein tag to hasten and improve the immunotherapy's ability to attack cancer cells.
Outcomes from a novel personalized cell therapy may be improved if specific subtypes of T cells are selected to attack diseases such as acute lymphoblastic leukemia and lymphoma.
Higher body weight and increased height during adolescence increase the risk for developing certain subtypes of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma.
[OncoTargets and Therapy] Anaplastic large cell lymphoma (ALCL) frequently involves the bone marrow, but primary or secondary involvement to the bone is rare. This article examines a case of anaplastic lymphoma kinase positive ALCL with prominent bone involvement in a young boy.
Peripheral T-cell lymphoma (PTCL) is a rare and aggressive form of cancer. This fact sheet explains the condition to newly diagnosed patients and provides sources of support.
- Mimicking Fasting During Chemotherapy Enhances T Cell Activity in Preclinical Study
- Transforming the Care of Patients With Thyroid Cancer
- Immunotherapy Combination Is Effective in Colorectal Cancer
- Blood Biomarker Is Predictive of Risk for Colon Cancer Recurrence
- Training Primary Care Providers to Screen for Melanoma Increases Diagnoses, With Little Affect on Dermatology Visits or Skin Surgeries
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Clinician Communication, Adherence to Protocols, and Presence of Pharmacists Improve Outcomes in ICUs
- Identifying Smaller ctDNA Fragments Improves Sensitivity of Liquid Biopsy
- Dual Antigen Targeting by CAR T Cells Improves Immunotherapeutic Technique
- Using Cognitive-Behavioral Therapy Principles in Daily Patient Interactions
- Decision Support and Shared Decision Making Help Patients Choose Plan for Low-Risk Prostate Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|